Xenon Pharmaceuticals is set to unveil Phase 3 trial results for its experimental epilepsy therapy azetukalner at the 16th European Epilepsy Congress in Athens next month.
The biotech firm will deliver six presentations, including an oral update on the X-TOLE2 study on September 7 from 12:15–1:45 p.m. EEST. A poster presentation detailing azetukalner’s mechanistic profile and in vivo data on its additive effects with standard antiseizure medications is also scheduled for September 6.
The X-TOLE2 trial randomized 380 adults with focal onset seizures to receive either azetukalner at 25 mg, 15 mg, or placebo as adjunctive therapy. Participants had a median of five prior antiseizure medications and an average baseline seizure frequency of 12.75 per month. Of the 332 who completed the double-blind phase, 322 entered an open-label extension study, with data presented for patients with at least 48 months of follow-up.
Azetukalner is being developed as a potassium channel opener for epilepsy, major depressive disorder, and bipolar depression. Xenon will host an exhibit booth at the congress from September 5–8, designated Booth #9.
Focal epilepsy affects roughly three million adults in the U.S., with up to half experiencing uncontrolled seizures despite existing treatments.
